High interpatient variability of treosulfan exposure is associated with early toxicity in paediatric HSCT: a prospective multicentre study

M. Y.Eileen C. van der Stoep, Alice Bertaina, Marloes H. ten Brink, Robbert G. Bredius, Frans J. Smiers, Dominique C.M. Wanders, Dirk Jan A.R. Moes, Franco Locatelli, Henk Jan Guchelaar, Juliëtte Zwaveling, Arjan C. Lankester

Research output: Contribution to journalArticle

Abstract

Treosulfan-based conditioning is increasingly employed in paediatric haematopoietic stem cell transplantation (HSCT). Data on treosulfan pharmacokinetics in children are scarce, and the relationship between treosulfan exposure, toxicity and clinical outcome is unresolved. In this multicentre prospective observational study, we studied treosulfan pharmacokinetics and the drug's relationship with regimen-related toxicity and early clinical outcome in 77 paediatric patients. Treosulfan dose was 30 g/m2, administered over 3 consecutive days in infants <1 year old (n = 12) and 42 g/m2 in children ≥1 year old (n = 65). Mean day 1 treosulfan exposure was 1744 ± 795 mg*h/l (10 g/m2) and 1561 ± 511 mg*h/l (14 g/m2), with an inter-individual variability of 56 and 33% in the respective groups. High treosulfan exposure (>1650 mg*h/l) was associated with an increased risk of mucosal [Odds ratio (OR) 4·40; 95% confidence interval (CI) 1·19–16·28, P = 0·026] and skin toxicity (OR 4·51; 95% CI 1·07–18·93, P = 0·040). No correlation was found between treosulfan exposure and the early clinical outcome parameters: engraftment, acute graft-versus-host disease and donor chimerism. Our study provides the first evidence in a large cohort of paediatric patients of high variability in treosulfan pharmacokinetics and an association between treosulfan exposure and early toxicity. Ongoing studies will reveal whether treosulfan exposure is related to long-term disease-specific outcome and late treatment-related toxicity.

Original languageEnglish
Pages (from-to)772-780
Number of pages9
JournalBritish Journal of Haematology
Volume179
Issue number5
DOIs
Publication statusPublished - Dec 1 2017

Fingerprint

treosulfan
Hematopoietic Stem Cell Transplantation
Multicenter Studies
Prospective Studies
Pediatrics
Pharmacokinetics
Odds Ratio
Confidence Intervals
Chimerism
Graft vs Host Disease

Keywords

  • conditioning regimen
  • paediatrics
  • pharmacokinetics
  • toxicity
  • treosulfan

ASJC Scopus subject areas

  • Hematology

Cite this

van der Stoep, M. Y. E. C., Bertaina, A., ten Brink, M. H., Bredius, R. G., Smiers, F. J., Wanders, D. C. M., ... Lankester, A. C. (2017). High interpatient variability of treosulfan exposure is associated with early toxicity in paediatric HSCT: a prospective multicentre study. British Journal of Haematology, 179(5), 772-780. https://doi.org/10.1111/bjh.14960

High interpatient variability of treosulfan exposure is associated with early toxicity in paediatric HSCT : a prospective multicentre study. / van der Stoep, M. Y.Eileen C.; Bertaina, Alice; ten Brink, Marloes H.; Bredius, Robbert G.; Smiers, Frans J.; Wanders, Dominique C.M.; Moes, Dirk Jan A.R.; Locatelli, Franco; Guchelaar, Henk Jan; Zwaveling, Juliëtte; Lankester, Arjan C.

In: British Journal of Haematology, Vol. 179, No. 5, 01.12.2017, p. 772-780.

Research output: Contribution to journalArticle

van der Stoep, MYEC, Bertaina, A, ten Brink, MH, Bredius, RG, Smiers, FJ, Wanders, DCM, Moes, DJAR, Locatelli, F, Guchelaar, HJ, Zwaveling, J & Lankester, AC 2017, 'High interpatient variability of treosulfan exposure is associated with early toxicity in paediatric HSCT: a prospective multicentre study', British Journal of Haematology, vol. 179, no. 5, pp. 772-780. https://doi.org/10.1111/bjh.14960
van der Stoep, M. Y.Eileen C. ; Bertaina, Alice ; ten Brink, Marloes H. ; Bredius, Robbert G. ; Smiers, Frans J. ; Wanders, Dominique C.M. ; Moes, Dirk Jan A.R. ; Locatelli, Franco ; Guchelaar, Henk Jan ; Zwaveling, Juliëtte ; Lankester, Arjan C. / High interpatient variability of treosulfan exposure is associated with early toxicity in paediatric HSCT : a prospective multicentre study. In: British Journal of Haematology. 2017 ; Vol. 179, No. 5. pp. 772-780.
@article{7e00860f60c148d2834dc4c32366d133,
title = "High interpatient variability of treosulfan exposure is associated with early toxicity in paediatric HSCT: a prospective multicentre study",
abstract = "Treosulfan-based conditioning is increasingly employed in paediatric haematopoietic stem cell transplantation (HSCT). Data on treosulfan pharmacokinetics in children are scarce, and the relationship between treosulfan exposure, toxicity and clinical outcome is unresolved. In this multicentre prospective observational study, we studied treosulfan pharmacokinetics and the drug's relationship with regimen-related toxicity and early clinical outcome in 77 paediatric patients. Treosulfan dose was 30 g/m2, administered over 3 consecutive days in infants <1 year old (n = 12) and 42 g/m2 in children ≥1 year old (n = 65). Mean day 1 treosulfan exposure was 1744 ± 795 mg*h/l (10 g/m2) and 1561 ± 511 mg*h/l (14 g/m2), with an inter-individual variability of 56 and 33{\%} in the respective groups. High treosulfan exposure (>1650 mg*h/l) was associated with an increased risk of mucosal [Odds ratio (OR) 4·40; 95{\%} confidence interval (CI) 1·19–16·28, P = 0·026] and skin toxicity (OR 4·51; 95{\%} CI 1·07–18·93, P = 0·040). No correlation was found between treosulfan exposure and the early clinical outcome parameters: engraftment, acute graft-versus-host disease and donor chimerism. Our study provides the first evidence in a large cohort of paediatric patients of high variability in treosulfan pharmacokinetics and an association between treosulfan exposure and early toxicity. Ongoing studies will reveal whether treosulfan exposure is related to long-term disease-specific outcome and late treatment-related toxicity.",
keywords = "conditioning regimen, paediatrics, pharmacokinetics, toxicity, treosulfan",
author = "{van der Stoep}, {M. Y.Eileen C.} and Alice Bertaina and {ten Brink}, {Marloes H.} and Bredius, {Robbert G.} and Smiers, {Frans J.} and Wanders, {Dominique C.M.} and Moes, {Dirk Jan A.R.} and Franco Locatelli and Guchelaar, {Henk Jan} and Juli{\"e}tte Zwaveling and Lankester, {Arjan C.}",
year = "2017",
month = "12",
day = "1",
doi = "10.1111/bjh.14960",
language = "English",
volume = "179",
pages = "772--780",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "John Wiley & Sons, Ltd (10.1111)",
number = "5",

}

TY - JOUR

T1 - High interpatient variability of treosulfan exposure is associated with early toxicity in paediatric HSCT

T2 - a prospective multicentre study

AU - van der Stoep, M. Y.Eileen C.

AU - Bertaina, Alice

AU - ten Brink, Marloes H.

AU - Bredius, Robbert G.

AU - Smiers, Frans J.

AU - Wanders, Dominique C.M.

AU - Moes, Dirk Jan A.R.

AU - Locatelli, Franco

AU - Guchelaar, Henk Jan

AU - Zwaveling, Juliëtte

AU - Lankester, Arjan C.

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Treosulfan-based conditioning is increasingly employed in paediatric haematopoietic stem cell transplantation (HSCT). Data on treosulfan pharmacokinetics in children are scarce, and the relationship between treosulfan exposure, toxicity and clinical outcome is unresolved. In this multicentre prospective observational study, we studied treosulfan pharmacokinetics and the drug's relationship with regimen-related toxicity and early clinical outcome in 77 paediatric patients. Treosulfan dose was 30 g/m2, administered over 3 consecutive days in infants <1 year old (n = 12) and 42 g/m2 in children ≥1 year old (n = 65). Mean day 1 treosulfan exposure was 1744 ± 795 mg*h/l (10 g/m2) and 1561 ± 511 mg*h/l (14 g/m2), with an inter-individual variability of 56 and 33% in the respective groups. High treosulfan exposure (>1650 mg*h/l) was associated with an increased risk of mucosal [Odds ratio (OR) 4·40; 95% confidence interval (CI) 1·19–16·28, P = 0·026] and skin toxicity (OR 4·51; 95% CI 1·07–18·93, P = 0·040). No correlation was found between treosulfan exposure and the early clinical outcome parameters: engraftment, acute graft-versus-host disease and donor chimerism. Our study provides the first evidence in a large cohort of paediatric patients of high variability in treosulfan pharmacokinetics and an association between treosulfan exposure and early toxicity. Ongoing studies will reveal whether treosulfan exposure is related to long-term disease-specific outcome and late treatment-related toxicity.

AB - Treosulfan-based conditioning is increasingly employed in paediatric haematopoietic stem cell transplantation (HSCT). Data on treosulfan pharmacokinetics in children are scarce, and the relationship between treosulfan exposure, toxicity and clinical outcome is unresolved. In this multicentre prospective observational study, we studied treosulfan pharmacokinetics and the drug's relationship with regimen-related toxicity and early clinical outcome in 77 paediatric patients. Treosulfan dose was 30 g/m2, administered over 3 consecutive days in infants <1 year old (n = 12) and 42 g/m2 in children ≥1 year old (n = 65). Mean day 1 treosulfan exposure was 1744 ± 795 mg*h/l (10 g/m2) and 1561 ± 511 mg*h/l (14 g/m2), with an inter-individual variability of 56 and 33% in the respective groups. High treosulfan exposure (>1650 mg*h/l) was associated with an increased risk of mucosal [Odds ratio (OR) 4·40; 95% confidence interval (CI) 1·19–16·28, P = 0·026] and skin toxicity (OR 4·51; 95% CI 1·07–18·93, P = 0·040). No correlation was found between treosulfan exposure and the early clinical outcome parameters: engraftment, acute graft-versus-host disease and donor chimerism. Our study provides the first evidence in a large cohort of paediatric patients of high variability in treosulfan pharmacokinetics and an association between treosulfan exposure and early toxicity. Ongoing studies will reveal whether treosulfan exposure is related to long-term disease-specific outcome and late treatment-related toxicity.

KW - conditioning regimen

KW - paediatrics

KW - pharmacokinetics

KW - toxicity

KW - treosulfan

UR - http://www.scopus.com/inward/record.url?scp=85031670430&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85031670430&partnerID=8YFLogxK

U2 - 10.1111/bjh.14960

DO - 10.1111/bjh.14960

M3 - Article

C2 - 29048102

AN - SCOPUS:85031670430

VL - 179

SP - 772

EP - 780

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 5

ER -